logo
Monumental Energy Announces Commencement of Copper Moki Workovers in New Zealand

Monumental Energy Announces Commencement of Copper Moki Workovers in New Zealand

Business Wire20-05-2025

VANCOUVER, British Columbia--(BUSINESS WIRE)--Monumental Energy Corp. (' Monumental ' or the ' Company ') (TSX-V: MNRG; FSE: ZA6; OTCQB: MNMRF) is pleased to announce that workover operations have commenced at the Copper Moki-1 and Copper Moki-2 wells, located in the Taranaki Basin, New Zealand.
The workover program being carried out in conjunction with the Company's partner, New Zealand Energy Corp., involves re-entering both wells to perform downhole cleanouts, replace tubing and rods, and perforate the Mt. Messenger formation. The objective is to restore production from the Mt. Messenger sands and resolve known flow restrictions identified in previous operations.
Additionally, the wells have never undergone a full tubing replacement or sand cleanout, providing Monumental with the opportunity to perforate an unproduced zone. Having remained idle for 18 months, the wells also present potential for a significant flush production increase, further enhanced by the planned perforation of an additional 5-metre interval in the Mt. Messenger formation.
Copper Moki-1 Workover Highlights:
The well, drilled to a depth of 2,220-metres with 7' casing set at 2,214-metres, will be re-entered to retrieve approximately 600-metres of parted sucker rods and remove wax and sand buildup.
A 5-metre interval of the Mt. Messenger formation, located at approximately 1,587 metres, will be perforated to access untapped hydrocarbon zones.
New tubing, a tubing anchor, and a complete pump string will be installed to optimize production efficiency.
The well will be fully equipped with a pump and rod system, after which flow testing will be conducted in preparation for a return to production.
Copper Moki-2 Workover Highlights:
The 2,084-metre well will undergo similar operations to Copper Moki-1, including a full tubing replacement and comprehensive well cleanout.
A new pump and rod system will be installed to enable production from the newly perforated zone.
As with Copper Moki-1, well pressure is several hundred psi below hydrostatic, suggesting favourable conditions for drawdown and early production.
Max Sali, Vice President of Corporate Development and Director, commented: "These workovers represent a meaningful step toward monetizing the Taranaki Basin assets. With infrastructure in place, we are well-positioned to restore production and potentially generate early cash flow to support Monumental's broader strategic objectives. We are also pleased to have a newly upgraded rig on site, which is now fully operational and will enable the expedited execution of future projects.'
Field operations are expected to be completed in the coming weeks, with initial production results anticipated shortly thereafter. To date, the program remains under budget; Monumental does not anticipate any further expenditures until the workover is complete and flush production begins. Total spending to date is approximately NZD $560,000 (CAD $460,000).
About Monumental Energy Corp.
Monumental Energy Corp. is an exploration company focused on the acquisition, exploration, and development of properties in the critical and clean energy sector, as well as investing in oil and gas projects. The Company owns securities of New Zealand Energy Corp. and entered into a call option and royalty agreement on the Copper Moki wells with New Zealand Energy Corp. The Company also has an option to acquire a 75% interest and title to the Laguna cesium-lithium brine project located in Chile. The Company holds a 2% net smelter return royalty on Summit Nanotech's share of any future lithium production from the Salar de Turi Project.
On behalf of the Board of Directors,
/s/ 'Michelle DeCecco'
Michelle DeCecco, CEO
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Information
This news release contains 'forward‐looking information or statements' within the meaning of applicable securities laws, which may include, without limitation, completing the Copper Moki 1 & 2 workovers and the expected results, the expected timeline to complete the workovers of Copper Moki 1 & 2 wells, and commencement of production of CM 1 & 2, potential oil and gas transactions, other statements relating to the technical, financial and business prospects of the Company, its projects, its goals and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of metals and the price of oil and gas, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner and that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company's views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties relating to the interpretation of exploration results, risks related to the inherent uncertainty of exploration and cost estimates and the potential for unexpected costs and expenses and those other risks filed under the Company's profile on SEDAR+ at www.sedarplus.ca. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, failure to secure personnel and equipment for work programs, adverse weather and climate conditions, risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of materials and equipment, government action or delays in the receipt of government approvals, industrial disturbances or other job action, and unanticipated events related to health, safety and environmental matters), risks relating to inaccurate geological assumptions, failure to maintain or obtain all necessary government permits, approvals and authorizations, failure to obtain or maintain surface access agreements or understandings from local communities, land owners or Indigenous groups, fluctuation in exchange rates, the impact of viruses and diseases on the Company's ability to operate, capital market conditions, restriction on labour and international travel and supply chains, decrease in the price of lithium, cesium and other metals, decrease in the price of oil and gas, loss of key employees, consultants, or directors, failure to maintain or obtain community acceptance (including from the Indigenous communities), increase in costs, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

Yahoo

time27 minutes ago

  • Yahoo

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) ('CERo'), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the 'Investors') pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including $5 million previously issued in April 2025 and up to $3 million issuable at the option of the Investors. The shares of Series D Preferred Stock are convertible into shares of the Company's common stock. 'We welcome this vote of confidence and the continued support of our investors as we continue to show progress along our clinical timeline. The completion of our first-in-human dosing represents a significant clinical development milestone in AML for CER-1236, a novel autologous CAR-T therapeutic candidate targeting TIM 4L, and we will continue to communicate results as the data matures,' said Chris Ehrlich, Chief Executive Officer. The gross proceeds to CERo from today's closing are expected to be approximately $750,000, with up to $2.25 million of cash that may be funded at one or more additional closings, at the election of the Investors. CERo intends to use the net proceeds from the offering to take advantage of the two recent FDA IND allowances in liquid and solid tumors and complete the previously announced site activation at MDACC, as well as bring other sites online quickly. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. In April 2025, CERo initiated clinical trials for its lead product candidate, CER-1236,for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 15, 2025, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact:Chris EhrlichChief Executive Officerchris@ Investors:CORE IRinvestors@ in to access your portfolio

US Capital Global Facilitates $50MM Financing to Accelerate Charbone Hydrogen's North American Expansion
US Capital Global Facilitates $50MM Financing to Accelerate Charbone Hydrogen's North American Expansion

Yahoo

time27 minutes ago

  • Yahoo

US Capital Global Facilitates $50MM Financing to Accelerate Charbone Hydrogen's North American Expansion

Global private financial group headquartered in San Francisco advises on construction facility to support Charbone's expansion of modular green hydrogen facilities in North America. About Charbone Hydrogen Corporation, and True Green Capital Management San Francisco, California, USA, June 06, 2025 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, the SEC-registered broker-dealer division of the global private financial group US Capital Global, is pleased to announce that it has acted as lead advisor and facilitator on a project finance facility of up to $50 million for Charbone Hydrogen Corporation (TSXV: CH; OTCQB: CHHYF; FSE: K47) ('Charbone'). The financing is being provided by a private fund managed by True Green Capital Management LLC ('TGC'). Headquartered in Montreal, Charbone is a rare publicly traded pure-play hydrogen company focused exclusively on the production and distribution of green hydrogen in North America. The company is developing modular production facilities targeting 99.999% purity (Grade 5.0) hydrogen, with all output pre-sold through tier-one offtake agreements. 'We're proud to have served as lead advisor to both Charbone and TGC on this transaction,' said Charles Towle, CEO of US Capital Global Securities. 'Charbone is gaining strong momentum as demand grows for clean hydrogen solutions to decarbonize the energy grid. With key sites in development across North America, we look forward to supporting the company's continued growth. The transaction was led by Lisa Terk, Senior Vice President and a top CleanTech and Renewables banker at our global headquarters.' 'This financing marks an important milestone in executing our long-term growth strategy,' said Benoit Veilleux, CFO of Charbone. 'We are grateful to US Capital Global for their consistent support and expertise throughout this process—from structuring and investor engagement to the successful completion of legal documentation.' Hervé Touati, Managing Director at TGC, added: 'We're pleased to be financing Charbone and look forward to working together on this joint renewable clean energy initiative. We appreciate the diligence and insight of US Capital Global in bringing this opportunity to this stage.' About Charbone Hydrogen Corporation Charbone Hydrogen Corporation is an integrated green hydrogen company developing a North American network of modular production facilities while also leveraging commercial partnerships to distribute hydrogen, helium, and other industrial gases. This dual approach enhances revenue potential, reduces capital intensity, and increases flexibility. Charbone's shares trade on the TSX Venture Exchange (TSXV: CH), OTC Markets (OTCQB: CHHYF), and Frankfurt Stock Exchange (FSE: K47). Learn more at About True Green Capital Management True Green Capital Management LLC ('TGC') is a specialized renewable energy infrastructure fund manager with a focus in distributed power generation in the US and Europe. Since 2011, TGC has financed and managed clean energy assets that generate stable, low-correlated returns. Headquartered in Westport, Connecticut, TGC also maintains an office in London. Learn more at About US Capital Global Founded in 1998, US Capital Global offers a range of advanced financial solutions, including debt, equity, and investment products customized for middle-market enterprises and investors. The firm oversees direct investment funds while delivering comprehensive wealth management and investment banking services, encompassing M&A strategies and capital raising expertise. Among the notable entities within the consortium are US Capital Global Investment Management LLC, US Capital Global Wealth Management LLC, and US Capital Global Securities LLC, an SEC-registered broker-dealer and member of FINRA. To learn more, visit For more information about this transaction, please contact Lisa Terk, Senior Vice President, at or call +1 About Charbone Hydrogen Corporation, and True Green Capital Management CONTACT: Vanessa Guajardo US Capital Global +1 415 889 1010 media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025
Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025

Associated Press

time27 minutes ago

  • Associated Press

Neural's Partner CWE to Open Store No. 16 in the City of Bonn and Invitation to Meet Hanf.com at Mary Jane Berlin 2025

Toronto, Ontario--(Newsfile Corp. - June 6, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ('Neural' or the 'Company'), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ('CWE'), operating as one of the Germany's leading CBD retailers, are pleased to provide an update on expansion efforts in Germany. A subsidiary of CWE has signed a franchise agreement to open the first in the City of Bonn-the former capital of The Federal Republic of Germany and home to over 320,000 residents. This marks 's fifth franchise agreement and the second store in the state of North Rhine-Westphalia. is also proud to announce its participation in Mary Jane Berlin 2025, Europe's premier cannabis trade show and festival, taking place June 19-22, 2025 at Messe Berlin. As part of the event's vibrant exhibition floor, will showcase its latest product innovations, including premium CBD oils, sustainable hemp-based wellness items, and exclusive new lifestyle offerings. Visitors can find at Booth #G19/G20, where they will be invited to explore, sample, and connect with the team behind one of the most trusted names in the hemp space. Alex Cerveny, COO of commented: 'We are excited to bring the experience to Bonn-a city with deep roots and a progressive spirit. This new franchise marks an important step in our mission to make high-quality CBD products accessible to customers across Germany. We look forward to serving the Bonn community with the same passion, integrity, and innovation that defines the brand.' 'We are also thrilled to be part of Mary Jane Berlin again this year and invite our friends, partners, and associates to come meet our team.' Mr. Cerveny added: 'This event is not just a trade show-it's a celebration of cannabis culture, innovation, and progress. We look forward to engaging with industry partners and consumers to showcase our carefully curated portfolio of CBD products, as we continue paving the way for opening more franchise locations.' Now in its ninth year, Mary Jane Berlin is expected to welcome over 60,000 visitors and more than 500 exhibitors from around the world. Programming includes expert panels, live music, food trucks, and a dedicated B2B business day. About Neural Therapeutics Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy. On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation. For further inquiries, please contact: Neural Therapeutics Inc. Ian Campbell, CEO E: [email protected] T: +1 (647) 697-NURL (6875) Marc Lakmaaker E: [email protected] T: +1.647.289.6640 CAUTIONARY DISCLAIMER STATEMENT No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ('FLS') relating opening of new franchise locations by CWE (operating as the timing and scope of participation at Mary Jane Berlin 2025, the growth and performance of business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies from the transaction between Neural and CWE, expected consumer reception of products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expect', 'plan' and similar expressions. These statements are not statements of historical fact, but rather predictions about future events, which are inherently subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management considers such information to be reasonable at the time of preparation, may prove to be incorrect and actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. The Company expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. Persons' (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. To view the source version of this press release, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store